Janux Therapeutics, Inc. (NASDAQ:JANX) Director Ra Capital Management, L.P. Buys 341,742 Shares

Janux Therapeutics, Inc. (NASDAQ:JANX) Director Ra Capital Management, L.P. bought 341,742 shares of the stock in a transaction that occurred on Wednesday, March 5th. The shares were bought at an average cost of $30.64 per share, with a total value of $10,470,974.88. Following the completion of the transaction, the director now owns 9,658,988 shares in the company, valued at $295,951,392.32. The trade was a 3.67 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Friday, March 7th, Ra Capital Management, L.P. purchased 110,206 shares of Janux Therapeutics stock. The stock was bought at an average cost of $31.02 per share, with a total value of $3,418,590.12.

Janux Therapeutics Price Performance

JANX stock opened at $30.64 on Monday. The company’s 50-day moving average is $41.27 and its 200-day moving average is $47.50. The stock has a market capitalization of $1.81 billion, a PE ratio of -26.19 and a beta of 3.23. Janux Therapeutics, Inc. has a 1 year low of $29.63 and a 1 year high of $71.71.

Janux Therapeutics (NASDAQ:JANX) last announced its quarterly earnings results on Thursday, February 27th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.49) by $0.13. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. On average, analysts anticipate that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts recently commented on JANX shares. Scotiabank reduced their target price on Janux Therapeutics from $62.00 to $41.00 and set a “sector perform” rating on the stock in a report on Friday, February 28th. Leerink Partnrs raised shares of Janux Therapeutics to a “strong-buy” rating in a research note on Friday, November 22nd. Lifesci Capital raised shares of Janux Therapeutics to a “strong-buy” rating in a research note on Friday, December 27th. Leerink Partners boosted their target price on shares of Janux Therapeutics from $79.00 to $91.00 and gave the company an “outperform” rating in a report on Tuesday, December 3rd. Finally, William Blair reiterated an “outperform” rating on shares of Janux Therapeutics in a report on Friday, January 10th. One investment analyst has rated the stock with a hold rating, ten have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Janux Therapeutics presently has an average rating of “Buy” and a consensus target price of $88.00.

Hedge Funds Weigh In On Janux Therapeutics

Large investors have recently modified their holdings of the company. Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in Janux Therapeutics during the fourth quarter worth $2,477,000. GF Fund Management CO. LTD. acquired a new position in shares of Janux Therapeutics during the fourth quarter valued at about $59,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of Janux Therapeutics by 532.7% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 165,737 shares of the company’s stock worth $8,874,000 after acquiring an additional 139,543 shares in the last quarter. Woodline Partners LP raised its holdings in shares of Janux Therapeutics by 15.7% in the 4th quarter. Woodline Partners LP now owns 1,852,187 shares of the company’s stock worth $99,166,000 after acquiring an additional 251,924 shares during the last quarter. Finally, Squarepoint Ops LLC lifted its position in Janux Therapeutics by 155.1% in the 4th quarter. Squarepoint Ops LLC now owns 41,176 shares of the company’s stock valued at $2,205,000 after acquiring an additional 25,034 shares in the last quarter. 75.39% of the stock is currently owned by institutional investors.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.